[{"address1": "11711 N. Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "(317) 659-0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk MBA", "age": 54, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 571200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven J. Prestrelski M.B.A., MBA, Ph.D.", "age": 59, "title": "Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 56, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 21.86, "open": 21.86, "dayLow": 21.5, "dayHigh": 23.225, "regularMarketPreviousClose": 21.86, "regularMarketOpen": 21.86, "regularMarketDayLow": 21.5, "regularMarketDayHigh": 23.225, "forwardPE": -9.594828, "volume": 60543, "regularMarketVolume": 60543, "averageVolume": 185482, "averageVolume10days": 106640, "averageDailyVolume10Day": 106640, "bid": 21.6, "ask": 22.63, "bidSize": 100, "askSize": 100, "marketCap": 743121152, "fiftyTwoWeekLow": 19.33, "fiftyTwoWeekHigh": 26.19, "fiftyDayAverage": 23.097647, "twoHundredDayAverage": 23.097647, "currency": "USD", "enterpriseValue": 449827040, "floatShares": 6554190, "sharesOutstanding": 33383700, "sharesShort": 363738, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0093, "heldPercentInsiders": 0.042940002, "heldPercentInstitutions": 0.76381, "shortRatio": 2.03, "bookValue": -6.182, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -47200000, "trailingEps": -1.48, "forwardEps": -2.32, "enterpriseToEbitda": -8.869, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MBX", "underlyingSymbol": "MBX", "shortName": "MBX Biosciences, Inc.", "longName": "MBX Biosciences, Inc.", "firstTradeDateEpochUtc": 1726234200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a066c197-b79d-33dd-be3a-0bcc20467a16", "gmtOffSetMilliseconds": -14400000, "currentPrice": 22.26, "targetHighPrice": 44.0, "targetLowPrice": 30.0, "targetMeanPrice": 37.25, "targetMedianPrice": 37.5, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 55262000, "totalCashPerShare": 3.49, "ebitda": -50717000, "totalDebt": 249000, "quickRatio": 6.761, "currentRatio": 7.173, "debtToEquity": 0.457, "operatingCashflow": -42852000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]